Loading clinical trials...

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE3

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

NCT06143878•Janssen Research & Development, LLC

View on ClinicalTrials.gov

Summary

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention
•Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
•Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
•Total investigator global assessment (IGA) \>=3 at screening and baseline
•Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria

•Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
•Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
•A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
•Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib, or to any of the excipients or components of the study intervention
•Major surgical procedure, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study

Locations (164)

Medical Dermatology Specialists

Phoenix, Arizona, United States

Center for Dermatology and Plastic Surgery

Scottsdale, Arizona, United States

Johnson Dermatology

Fort Smith, Arkansas, United States

First OC Dermatology

Fountain Valley, California, United States

Center for Dermatology Clinical Research

Fremont, California, United States

Integrative Skin Science and Research

Sacramento, California, United States

Southern California Dermatology

Santa Ana, California, United States

Clinical Science Institute

Santa Monica, California, United States

Driven Research LLC

Coral Gables, Florida, United States

Ziaderm Research LLC

North Miami Beach, Florida, United States

Key Dates

Start Date

February 1, 2024

Primary Completion Date

September 17, 2024

Completion Date

June 1, 2027

Last Updated

March 12, 2026

Enrollment

774

ACTUAL participants

Conditions

Plaque Psoriasis

Interventions

JNJ-77242113

DRUG

JNJ-77242113 Matching Placebo

DRUG

Deucravacitinib

DRUG

Deucravacitinib Matching Placebo

DRUG

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Plaque Psoriasis

View study

RECRUITINGPHASE2

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

NCT07449702

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 12, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Inclusion Criteria

Exclusion Criteria

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis